Polypeptide Group Ag Stock Cash And Equivalents
| PPGN Stock | CHF 28.95 0.45 1.58% |
PolyPeptide Group AG fundamentals help investors to digest information that contributes to PolyPeptide Group's financial success or failures. It also enables traders to predict the movement of PolyPeptide Stock. The fundamental analysis module provides a way to measure PolyPeptide Group's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to PolyPeptide Group stock.
PolyPeptide |
PolyPeptide Group AG Company Cash And Equivalents Analysis
PolyPeptide Group's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current PolyPeptide Group Cash And Equivalents | 136.3 M |
Most of PolyPeptide Group's fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, PolyPeptide Group AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
In accordance with the recently published financial statements, PolyPeptide Group AG has 136.3 M in Cash And Equivalents. This is 83.4% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The cash and equivalents for all Switzerland stocks is 94.96% higher than that of the company.
PolyPeptide Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses PolyPeptide Group's direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of PolyPeptide Group could also be used in its relative valuation, which is a method of valuing PolyPeptide Group by comparing valuation metrics of similar companies.PolyPeptide Group is currently under evaluation in cash and equivalents category among its peers.
PolyPeptide Fundamentals
| Return On Equity | 0.0809 | |||
| Return On Asset | 0.0467 | |||
| Profit Margin | 0.12 % | |||
| Operating Margin | 0.15 % | |||
| Current Valuation | 755.81 M | |||
| Shares Outstanding | 33.12 M | |||
| Shares Owned By Insiders | 59.60 % | |||
| Shares Owned By Institutions | 29.93 % | |||
| Price To Book | 1.90 X | |||
| Price To Sales | 2.82 X | |||
| Revenue | 282.13 M | |||
| Gross Profit | 100.91 M | |||
| EBITDA | 83.35 M | |||
| Net Income | 47.26 M | |||
| Cash And Equivalents | 136.3 M | |||
| Cash Per Share | 5.67 X | |||
| Total Debt | 14.95 M | |||
| Debt To Equity | 0.14 % | |||
| Current Ratio | 2.94 X | |||
| Book Value Per Share | 12.97 X | |||
| Cash Flow From Operations | 57.35 M | |||
| Earnings Per Share | 0.94 X | |||
| Target Price | 28.68 | |||
| Number Of Employees | 1.16 K | |||
| Market Capitalization | 823.49 M | |||
| Total Asset | 595.04 M | |||
| Z Score | 33.0 | |||
| Annual Yield | 0.01 % | |||
| Net Asset | 595.04 M | |||
| Last Dividend Paid | 0.29 |
About PolyPeptide Group Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze PolyPeptide Group AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PolyPeptide Group using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PolyPeptide Group AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for PolyPeptide Stock Analysis
When running PolyPeptide Group's price analysis, check to measure PolyPeptide Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PolyPeptide Group is operating at the current time. Most of PolyPeptide Group's value examination focuses on studying past and present price action to predict the probability of PolyPeptide Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PolyPeptide Group's price. Additionally, you may evaluate how the addition of PolyPeptide Group to your portfolios can decrease your overall portfolio volatility.